伊曲康唑注射液治疗血液病合并侵袭性真菌病临床分析

目的：探讨伊曲康唑注射液对血液病患者合并侵袭性真菌病分层治疗的疗效及安全性。方法回顾性分析160例血液病合并侵袭性真菌病患者接受伊曲康唑注射液分层治疗的疗效和安全性，并对相关影响因素进行回顾性分析。结果伊曲康唑对全部患者的总有效率为58.12%（93／160），其中经验治疗、诊断驱动治疗和目标治疗的有效率分别为65.82%（52／160）、53.57%（30／160）、44.00%（11／160），三组间的疗效差异无统计学意义（P＝0.054）。相关不良事件发生率为8.13%（13／160），主要为肝功能损害。多因素分析显示伊曲康唑注射液治疗侵袭性真菌病的疗效不受年龄、真菌感染病史、是否存在粒细胞缺乏、是否初治等因素的影响。结论伊曲康唑注射液对血液病患者合并侵袭性真菌病的各个分层治疗均有良好的疗效，且安全可靠。

Clinical analysis of intravenous itraconazole in different antifungal strategies for hematologic diseases patients with invasive fungal disease

Objective To investigate the efficacy and safety of intravenous itraconazole in different antifungal strategies for hematologic diseases patients with invasive fungal disease. Methods The efficacy and safety of intravenous itraconazole injection in the treatment of 160 hematologic diseases patients with invasive fungal disease, including the related factors were retrospectively analysed. Results The total efficacy rate of itraconazole was 58.12 %(93/160). The response rates in therapy for undefined patients without any evidence of patients, diagnostic-driven therapy for possible IFD patients, targeted therapy for proven IFD patients were 65.82 %(52/79), 53.57 %(30/56) and 44.00 %(11/25), respectively (P=0.054). The incidence rate of itraconazole-related adverse effect was 8.13 % (13/160), and the main adverse reaction was liver impairment. Multiple-factor analysis showed that the efficacy of itraconazole for the treatment of hematologic diseases patients with invasive fungal disease was not associated with age, medical history, agranulocytosis, and initial treatment. Conclusion Itraconazole itraconazole is effective and safe in the treatment of fungal therapy for patients with hematologic diseases.